Matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome

Basit Öğe Kaydı
dc.authoridYildirim, Nilgun/0000-0001-6266-4951
dc.contributor.authorKara, Selcuk
dc.contributor.authorYildirim, Nilgun
dc.contributor.authorOzer, Ahmet
dc.contributor.authorColak, Omer
dc.contributor.authorSahin, Afsun
dc.date.accessioned2025-01-27T21:19:33Z
dc.date.available2025-01-27T21:19:33Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose: The aim of the study reported in this article was to determine the presence and quantitative differences of matrix metalloproteinase-2 (MMP-2), its tissue inhibitor (TIMP-2) and transforming growth factor beta 1 (TGF-beta 1) in the aqueous humor and serum samples of patients with pseudoexfoliation (PEX) syndrome. Methods: Aqueous humor and serum samples were collected from 32 patients with PEX syndrome (with and without glaucoma) and a control group, who underwent routine cataract surgery. Levels of MMP-2, TIMP-2, and TGF-beta 1 were determined by specific immunoassays (enzyme-linked immunosorbent assay). Results: MMP-2, TIMP-2, and TGF-beta 1 were identified in aqueous humor and serum samples from all groups of patients. The aqueous and serum samples of MMP-2, TIMP-2, and TGF-beta 1 showed no significant differences between PEX syndrome and control groups. Serum levels of MMP-2, TIMP-2, and TGF-beta 1 were statistically greater than their aqueous levels (P<0.05), except for TIMP-2 levels in the control group. Conclusion: No statistically significant difference among mean MMP-2, TIMP-2, and TGF-beta 1 levels in both aqueous humor and serum samples was found between patients with PEX syndrome and the control group. It is important to simultaneously evaluate serum and aqueous samples from patients with PEX syndrome, which is related to an impaired blood-aqueous barrier.
dc.identifier.doi10.2147/OPTH.S55914
dc.identifier.endpage309
dc.identifier.issn1177-5483
dc.identifier.pmid24511224
dc.identifier.scopus2-s2.0-84893359884
dc.identifier.scopusqualityQ2
dc.identifier.startpage305
dc.identifier.urihttps://doi.org/10.2147/OPTH.S55914
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28658
dc.identifier.volume8
dc.identifier.wosWOS:000216106700041
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofClinical Ophthalmology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectMMP-2
dc.subjectTIMP-2
dc.subjectTGF-beta 1
dc.subjectPEX glaucoma
dc.subjectPEX syndrome
dc.titleMatrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu